Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis
Keratoconjunctivitis, Vernal
About this trial
This is an interventional treatment trial for Keratoconjunctivitis, Vernal
Eligibility Criteria
Inclusion Criteria: Patients with vernal keratoconjunctivitis, mild or moderate : clinical score >3 and <= 14, calculated from 4 major symptoms (itching, tearing, photophobia, foreign body sensation) and 6 major clinical signs (conjunctival erythema, conjunctival chemosis, discharge, papillae, limbal infiltrates and corneal epithelial disease) age >= 4 years old Exclusion Criteria: no occurrence of ocular trauma or infection (within the 3 months preceding the study), no ocular medical treatment (topical or not) within the 5 days preceding the study, no ocular laser (within the 3 previous months), no ocular surgery (within the previous year), patient who signs the informed consent form (or his/her parents or legal guardian in the case of underage patient).